- Home
- KLXE vs CVM Comparison
KLXE vs CVM Comparison
Compare KLXE & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLXE | CVM |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 41.2M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | KLXE | CVM |
|---|---|---|
| Price | $2.34 | $4.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 242.0K | 78.9K |
| Earning Date | 03-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $645,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $1.98 |
| 52 Week High | $5.29 | $20.41 |
Technical Indicators
Market Signals| Indicator | KLXE | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 44.61 |
| Support Level | $2.01 | $4.73 |
| Resistance Level | $3.45 | $5.49 |
| Average True Range (ATR) | 0.30 | 0.53 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 22.92 | 22.01 |
Price Performance
Historical ComparisonAbout KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.